Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Pipeline Review, H1 2017 Summary Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2017, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different Rand proteins produces different receptors which with Rand1 acts as a receptor for calcitonin-gene-related peptide, with Rand2 acts as a receptor for adrenomedullin-1and with Rand3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 6 and 3 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders and Undisclosed which include indications Migraine, Inflammatory Pain, Dental Pain, Diabetic Neuropathy, Nerve Injury, Neuropathic Pain, Post-Operative Pain, Stable Angina and Unspecified. Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects - The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development Allergan Plc Amgen Inc Biohaven Pharmaceutical Holding Company Ltd Eli Lilly and Company Fortress Biotech Inc Merck & Co Inc Teva Pharmaceutical Industries Ltd Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles A-100 - Drug Profile Product Description Mechanism Of Action R&D Progress AA-71 - Drug Profile Product Description Mechanism Of Action R&D Progress AFAP-3 - Drug Profile Product Description Mechanism Of Action R&D Progress AGN-241689 - Drug Profile Product Description Mechanism Of Action R&D Progress Atogepant - Drug Profile Product Description Mechanism Of Action R&D Progress BHV-3500 - Drug Profile Product Description Mechanism Of Action R&D Progress CGRP - Drug Profile Product Description Mechanism Of Action R&D Progress erenumab - Drug Profile Product Description Mechanism Of Action R&D Progress MK-8825 - Drug Profile Product Description Mechanism Of Action R&D Progress Rimegepant sulfate - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize CALCRL for Migraine - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CGRP for Migraine - Drug Profile Product Description Mechanism Of Action R&D Progress ubrogepant - Drug Profile Product Description Mechanism Of Action R&D Progress Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones Featured News & Press Releases Jun 08, 2017: Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society Jun 08, 2017: Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting May 18, 2017: Amgen Submits Biologics License Application To The FDA For Erenumab May 18, 2017: Heptares to Receive US$5 Million Milestone Payment from Teva Nov 16, 2016: Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study Sep 28, 2016: Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In First Phase 3 Study Sep 15, 2016: Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine Sep 15, 2016: Novartis announces new positive data showing AMG 334 significantly reduces monthly migraine days in chronic migraine vs placebo Sep 14, 2016: Amgen present erenumab at webcast call Jun 08, 2016: Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine Jun 19, 2015: Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine May 15, 2015: Amgen Presents First Phase 2 Data For AMG 334 In The Prevention Of Episodic Migraine May 11, 2015: Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Allergan Plc, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by Fortress Biotech Inc, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 Pipeline by Vertex Pharmaceuticals Inc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
